Provided by Tiger Trade Technology Pte. Ltd.

Guardant Health Inc.

168.33
-2.3600-1.38%
Post-market: 168.330.00000.00%19:30 EDT
Volume:2.20M
Turnover:371.14M
Market Cap:22.59B
PE:-48.04
High:171.55
Open:166.50
Low:165.00
Close:170.69
52wk High:191.05
52wk Low:61.00
Shares:134.20M
Float Shares:129.78M
Volume Ratio:1.07
T/O Rate:1.70%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.5037
EPS(LYR):-3.3203
ROE:-4584.47%
ROA:-18.07%
PB:-101.36
PE(LYR):-50.70

Loading ...

Guardant Health is Maintained at Overweight by Barclays

Dow Jones
·
Yesterday

Barclays Sticks to Its Buy Rating for Guardant Health (GH)

TIPRANKS
·
Yesterday

Guardant Health Inc Stock (GH) Moved Down by 8.27% on Oct 6: What Investors Need To Know

TradingKey
·
Yesterday

Movement Alert|Guardant Health Inc. Falls 5.36% in Regular Trading, Profit-Taking After Multi-Catalyst Rally

Market Focus
·
Oct 06

Movement Alert|Guardant Health Inc. Rises 5.07% in Regular Trading, UBS Report Highlights Liquid Biopsy Tailwinds

Market Focus
·
Oct 06

Guardant Health reports COSMOS study published in Cancer Research Communications

TIPRANKS
·
Oct 05

Guardant Health Cosmos-MEL01 Study Shows Guardant Reveal Detects 81% of Distant Melanoma Recurrences

Reuters
·
Oct 05

Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acromegaly

GlobeNewswire
·
Oct 05

Guardant Health price target raised to $200 from $190 at Guggenheim

TIPRANKS
·
Oct 01

S&P 500 Futures Drop in Premarket Trading; Moog, AngloGold Ashanti Lag

Dow Jones
·
Sep 28

Guardant Health (GH) Receives a Buy from Bernstein

TIPRANKS
·
Sep 26

FDA Advisors Said it Should Approve the Grail Multicancer Blood Test. the Stock Rises Sharply.

Dow Jones
·
Sep 24

Guardant Health Director Tariq Musa Sells 116 Common Shares for $20,300

Reuters
·
Sep 18

US Health Secretary Kennedy Jr. Adds Eight New Members to Key Health Committee

Reuters
·
Sep 17

Guardant Health on Track for Record High Close

Dow Jones
·
Sep 17

Guardant Health Could Benefit From AstraZeneca Trial Failure, UBS Says

MT Newswires Live
·
Sep 16

Movement Alert|Guardant Health Inc. Rises 5.31% in Regular Trading, Shield Blood Test Secures Major New Insurance Coverage Agreement

Market Focus
·
Sep 16

Guardant Health CIO Kumud Kalia Disposes of 4,000 Common Shares Worth $632,193.20

Reuters
·
Sep 15

Guardant Health, - Evicore by Evernorth to Cover Shield Blood Test for Crc Screening Effective Jan 1, 2027

THOMSON REUTERS
·
Sep 15

UBS Adjusts Guardant Health Price Target to $225 From $175, Maintains Buy Rating

MT Newswires Live
·
Sep 09